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Background: Patients with chronic obstructive pulmonary disease (COPD) demonstrate 
  variable responses to inhaled corticosteroids (ICS). The factors contributing to this variability are 
not well understood. Data from patients with asthma have suggested that low 25-hydroxyvitamin 
D [25(OH)D] levels contribute to a lack of ICS response in asthma. The objective of this study 
was to determine whether serum levels of 25(OH)D were related to ICS responses in patients 
with COPD.
Methods: A total of 60 exsmokers with severe COPD (mean forced expiratory volume in one 
second [FEV1] 1.07 L, 36% of predicted) spent 4 weeks free of any ICS, followed by 4 weeks 
of ICS use (fluticasone propionate 500 µg twice daily). Spirometry was performed prior to and 
after 4 weeks of ICS use. Blood 25(OH)D levels were measured prior to ICS use and examined 
for relationships to changes in FEV1 following the 4 weeks of ICS use.
Results: The mean 25(OH)D level was 23.3 ± 9.3 ng/mL. There was a high prevalence of 
  vitamin D insufficiency (35%) and deficiency (40%). There was no relationship between baseline 
25(OH)D and changes in FEV1 following 4 weeks of ICS.
Conclusion: Baseline 25(OH)D does not contribute to the variation in short-term FEV1 
responses to ICS in patients with severe COPD.
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Introduction
Vitamin D has received increasing amounts of attention in recent years, particularly 
its potential nonskeletal effects in diseases such as cancer, cardiovascular disease, and 
infectious diseases. Although an optimal level of vitamin D has not been defined for 
nonskeletal outcomes, 25-hydroxyvitamin D [25(OH)D] levels ,20 ng/mL are widely 
considered to reflect deficiency. Using this definition, patients with chronic obstructive 
pulmonary disease (COPD) have a high prevalence of vitamin D deficiency, ranging 
from approximately 30% in mild COPD to over 75% in severe COPD.1–5 The clinical 
consequences of these low 25(OH)D levels in COPD patients have not been studied 
extensively. Among patients with asthma, low 25(OH)D levels have been associated 
with an increased risk of severe asthma exacerbations,6 hospitalizations,7 poor asthma 
control,8 and steroid resistance.9 We pursued the current study to investigate relation-
ships between 25(OH)D and responses to inhaled corticosteroid (ICS) treatment in 
patients with COPD.
ICS are widely used in the treatment of COPD. However, the clinical response to 
ICS is variable, and some patients respond more favorably than others. The   underlying 
causes of this variable response are not well understood. Recent data from patients International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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with asthma suggest that low blood 25(OH)D levels might 
contribute to poor glucocorticoid responses.10,11 We there-
fore examined the hypothesis that among patients with 
COPD, 25(OH)D levels were associated with the variation 
in   responsiveness to ICS treatment.
Methods
This study was conducted using stored serum from a previ-
ous study designed to examine the ability of exhaled nitric 
oxide and blood markers of systemic inflammation to predict 
forced expiratory volume in one second (FEV1) responses 
to ICS treatment in patients with COPD. Results have been 
previously published.12
Subjects
The institutional review board of the Minneapolis   Veterans 
Affairs Medical Center approved the original study and this 
secondary analysis. All subjects provided written informed 
consent for the original study and for storage of blood 
samples for future research. The study did not meet trial 
registration criteria at the time of its conduct between 2005 
and 2006.
Subjects were recruited from the Minneapolis Veterans 
Affairs Medical Center between May 2005 and   February 
2006. Inclusion criteria were: 1) a clinical diagnosis of 
COPD, with a FEV1/forced vital capacity (FVC) ratio ,70%, 
and FEV1 ,60% of predicted; 2) age .45 years; 3) cigarette 
smoking history of .10 pack-years; 4) abstinence from ciga-
rette smoking of at least 6 months; 5) stable clinical status, as 
evidenced by the lack of hospitalizations, urgent care visits, 
antibiotics, or changes in medications within 4 weeks prior 
to enrollment; and 6) ability to provide informed consent. 
Exclusion criteria were: 1) a clinical diagnosis of asthma; 
2) leukotriene inhibitor use; 3) severe or uncompensated 
heart failure; 4) the presence of conditions known to elevate 
C-reactive protein (CRP) levels such as collagen vascular 
disease and chronic infection; 5) malignancy requiring 
active treatment with chemotherapy or radiation therapy, 
or any comorbidity making survival longer than 1 year 
unlikely; 6) women who were pregnant or lactating; 7) oral 
corticosteroid use within 4 weeks prior to enrollment; and 
8) participation in another investigational trial within 4 weeks 
of enrollment and for the 8-week duration of this study.
Study design
Subjects who met study criteria and agreed to participate 
entered a 4-week run-in period. During the run-in, subjects 
were treated with salmeterol, 50 µg inhalation twice daily 
(Serevent Diskus®; GlaxoSmithKline, Research Triangle 
Park, NC). The use of ICSs was not allowed during the 
run-in. Tiotropium use was not allowed for the duration of 
the study; however, tiotropium was not in wide use at the 
time of this study. Subjects were allowed to continue use of 
all other respiratory medications, including short-acting beta 
agonists and ipratropium.
After the run-in, subjects returned to the study center for 
baseline measurements of prebronchodilator spirometry and 
blood collection. All visits were in the morning and subjects 
were fasting. Before each study visit, subjects withheld 
use of short-acting bronchodilators for 6 hours and with-
held use of salmeterol for 12 hours. For the next 4 weeks, 
subjects were treated twice daily with 500 µg of fluticasone 
propionate and 50 µg of salmeterol (Advair Diskus 500/50®; 
  GlaxoSmithKline). After 4 weeks, subjects returned to the 
study center for repeat measurement of prebronchodilator 
spirometry and blood sample collection.
Protocols
Spirometry was performed in accordance with American 
Thoracic Society (ATS) standards13 (MicroLab 3500, Micro-
Medical, Kent, UK). Third National Health and Nutrition 
Examination Survey spirometric reference values were used 
as reference.14
Serum blood samples were allowed to clot at room 
temperature, centrifuged, and immediately frozen at -80°C 
in aliquots. Stored serum for 25(OH)D assay was available 
for all patients who completed the original study. For this 
study, 25(OH)D levels were measured from stored samples 
collected at the visit following the run-in (“baseline”), 
prior to ICS initiation. 25(OH)D was measured by liquid 
chromatography tandem mass spectroscopy (ThermoFisher 
Scientific, Franklin, MA; Applied Biosystems-MDS Sciex, 
Foster City, CA) at the Mayo Clinic Immunochemical Core 
Laboratory (Rochester, MN).
Statistical methods
The primary outcomes of interest in the original study were 
correlations between potential predictor variables (exhaled 
breath and blood inflammatory markers) and the outcome 
variable: prebronchodilator change in FEV1 from baseline 
to after 4 weeks of ICS therapy. The study was powered 
(two-sided alpha of 0.05 and beta of 0.20) to detect a cor-
relation coefficient of 0.35. This resulted in a sample size 
calculation of 62 patients. Seventy-eight subjects consented, 
which allowed for 20% of consented subjects to either fail 
spirometry screening or not complete the full protocol. International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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This secondary analysis of 25(OH)D levels as a predictor 
variable of ICS response was not planned at the time of the 
original study.
Because ICS responses were not normally distributed, 
analyses were conducted with nonparametric statistical 
tests. For the primary correlation analyses, Spearman’s 
rank-correlation testing (reported as Spearman’s rho) was 
used. For secondary analyses, we dichotomized subjects into 
responders and nonresponders to ICS therapy, using a FEV1 
improvement of $200 mL after 4 weeks of ICS therapy to 
define responders. There is no consensus on a meaningful 
FEV1 response to ICS therapy in COPD. We thus extrapolated 
from ATS guidelines which require $200 mL improve-
ment in FEV1 as a component of defining a   significant 
  bronchodilator response.13
Distributions of 25(OH)D among responders and non-
responders were compared using the Wilcoxon rank-sum 
test. Receiver-operating characteristic (ROC) analyses were 
also conducted, using FEV1 improvement of $200 mL after 
4 weeks of ICS therapy as the outcome of interest. We also 
dichotomized subjects using conventional 25(OH)D cut 
points for vitamin D deficiency (,20 ng/mL) and insuf-
ficiency (,30 ng/mL) and compared distributions of FEV1 
change using the Wilcoxon rank-sum test.
All statistical analyses were performed using Stata 
  software (v. 9; StataCorp LP, College Station, TX).
Results
A total of 76 patients consented to study participation, and 
16 (21%) did not complete the full protocol. Three failed to 
meet screening spirometry criteria, seven experienced COPD 
exacerbations during the study, and six withdrew consent 
during the study, chiefly for subjective dyspnea. Therefore, 
60 patients provided complete data for analysis. Compared 
to participants who completed the study, participants who 
withdrew from the study had similar COPD severity, but 
were more likely to have been prescribed antibiotics and 
prednisone in the previous 12 months, and were more likely 
to have received more inhaled medications, including inhaled 
corticosteroids, before study participation (Table 1).
The mean age was 71 years (98% males), with a mean 
FEV1 of 1.07 L ± 0.36 L (36% of predicted). ICS com-
pliance was excellent (93% of expected doses used) as 
assessed by device dose delivery counters. FEV1 change 
after ICS treatment ranged from -0.49 to 0.64 L (median 
change of 0.07 L; interquartile range, -0.02–0.14 L). Mean 
25(OH)D level was 23.3 ± 9.3 ng/mL. There was no correla-
tion between baseline 25(OH)D levels and baseline FEV1 
  (Spearman rho = -0.10; P = 0.46)   (Figure 1). There was 
a high prevalence of vitamin D deficiency (n = 24; 40%) 
when using the standard definition of deficiency being a 
25(OH)D level ,20 ng/mL. Vitamin D   insufficiency, defined 
as a 25(OH)D level $20 ng/mL but ,30 ng/mL, was also 
prevalent (n = 21, 35%). Only 25% of study participants had 
a 25(OH)D level considered normal.
There was no correlation between baseline 25(OH)D and 
subsequent FEV1 responses to ICS (Spearman rho = 0.01; 
P = 0.93) (Figure 2). When ICS responders were defined 
as experiencing $200 mL improvement in prebroncho-
dilator FEV1 between baseline and after ICS therapy, the 
median baseline 25(OH)D of ICS responders (n = 11) and 
  nonresponders (n = 49) was equal (23 ng/mL and 23 ng/mL, 
respectively; Wilcoxon rank-sum, P = 0.97) (Figure 3). 
ROC analysis showed that 25(OH)D had no ability to dis-
criminate ICS responders from nonresponders (ROC area 
under curve = 0.50; 95% confidence interval: 0.31–0.68). 
When patients were dichotomized as vitamin D deficient 
(25[OH]D ,20 ng/mL) or not deficient, there was no dif-
ference in the median FEV1 improvement with ICS in each 
group (75 mL and 50 mL, respectively; Wilcoxon rank-sum, 
P = 0.64) (Figure 4). Results did not change when the 25(OH)
D cutoff was changed to ,30 ng/mL to compare those with 
vitamin D insufficiency or deficiency to those with normal 
vitamin D levels (median FEV1 improvement of 80 mL and 
50 mL, respectively; Wilcoxon rank-sum, P = 0.78).
Discussion
This study utilized stored samples from a previous study 
examining predictors of ICS responses in patients with COPD. 
In the original study, exhaled nitric oxide was shown to have a 
modest relationship to ICS responses. In this   secondary analy-
sis of stored samples from that study, baseline 25(OH)D had 
no relationship to FEV1 changes after 4 weeks of ICS use.
This secondary analysis was largely prompted by Suther-
land and colleagues’ findings.10 In their sample of 54 adults 
with asthma, low 25(OH)D levels were associated with 
blunted corticosteroid responses. However, corticosteroid 
responses in their study were assessed by an in-vitro assay 
of dexamethasone-induced mitogen-activated protein kinase 
phosphatase (MKP)-1 expression by peripheral blood mono-
nuclear cells (PBMCs), rather than spirometry. As such, 
the clinical extension of their in vitro finding remains to be 
validated. In a related study of 100 children with asthma, 
Searing and colleagues reported similar in vitro effects of 
vitamin D on dexamethasone-induced MKP-1 expression 
by PBMCs.11 Relationships between vitamin D and steroid International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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Table 1 Characteristics of study sample at time of enrollment
Baseline characteristics at screening Completed study 
(n = 60)
Withdrawn from study 
(n = 13)
Demographics and smoking history
Male 59 (98%) 13 (100%)
Female 1 (2%) 0 (0%)
Age (years) 71 ± 7.3 70 ± 7.9
Smoking history (pack-years) 57 ± 30.6 53 ± 26.1
Duration of smoking abstinence (years) 13 ± 10 13 ± 9.4
Spirometry
Prebronchodilator FeV1 (L)  1.07 ± 0.36 1.09 ± 0.28
Prebronchodilator FeV1 (% predicted) 35.6 ± 10.6 33.0 ± 8.5
Prebronchodilator FVC (L) 2.44 ± 0.72 2.54 ± 0.62
Prebronchodilator FVC (% predicted) 58.5 ± 14.6 56.8 ± 12.9
Medication use
Prescribed one or more courses of antibiotics in the  
12 months prior to enrollment 
11 (18%) 6 (46%)
Prescribed one or more courses of prednisone in the  
12 months prior to enrollment
7 (12%) 6 (46%)
Prescribed chronic oxygen 10 (16%) 3 (23%)
Prescribed albuterol 59 (98%) 12 (92%)
Prescribed ipratropium 35 (58%) 11 (84%)
Prescribed long-acting beta agonist 30 (50%) 9 (69%)
Prescribed long-acting anticholinergic 1 (2%) 0 (0%)
Prescribed inhaled corticosteroid 28 (47%) 9 (69%)
Prescribed theophylline 2 (3%) 0 (0%)
Comorbid conditions
Coronary artery disease 16 (27%) 1 (8%)
heart failure 6 (12%) 1 (8%)
hypertension 36 (60%) 8 (62%)
Atrial fibrillation/flutter 5 (8%) 0 (0%)
hyperlipidemia 37 (62%) 8 (62%)
Diabetes mellitus 14 (23%) 1 (8%)
Peripheral vascular disease 9 (15%) 1 (8%)
history of stroke 2 (3%) 0 (0%)
Chronic kidney disease 5 (8%) 0 (0%)
Obstructive sleep apnea 4 (7%) 0 (0%)
Gastroesophageal reflux disease 12 (20%) 1 (8%)
Chronic rhinosinusitis 5 (8%) 1 (8%)
Note: Data are presented as mean ± standard deviation for continuous variables or as number (%) for categorical variables.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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Figure 2 Scatterplot of baseline (pre-ICS) 25(Oh)D and change in prebronchodilator 
FeV1 following 4 weeks of ICS. Spearman’s rank-correlation test used for calculation 
of Spearman rho and corresponding P value. 
Abbreviations: 25(Oh)D, 25-hydroxyvitamin D; FeV1, forced expiratory volume 
in 1 second; ICS, inhaled corticosteroid.
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Figure  3  Boxplots  of  baseline  (pre-ICS)  25(Oh)D  distributions  among  ICS 
nonresponders and ICS responders. ICS responders were defined as experiencing 
$200 mL FeV1 improvement following 4 weeks of ICS. Wilcoxon rank-sum test 
used for calculation of P value. 
Abbreviations: 25(Oh)D, 25-hydroxyvitamin D; FeV1, forced expiratory volume 
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Figure 4 Boxplots of distributions in FeV1 responses to ICS among study participants 
with vitamin D deficiency [25(OH)D ,20 ng/mL] versus no deficiency. Wilcoxon 
rank-sum test used for calculation of P value. 
Abbreviations: 25(Oh)D, 25-hydroxyvitamin D; FeV1, forced expiratory volume 
in 1 second; ICS, inhaled corticosteroid.
eliminated the need for a wash-out, but such a study was 
felt to be unfeasible for a single-center study, due to a high 
rate of use of ICS in patients with COPD (nearly 50% in 
our recruited sample).
Another limitation of our study is that nonspirometric 
  outcomes were not assessed, so an analysis of 25(OH)D 
relationships to outcomes such as acute exacerbations or 
respiratory health status could not be performed.   Compared 
with patients without COPD, patients with COPD are also at 
increased risk of diseases such as cardiovascular disease, osteo-
porosis, and skeletal muscle dysfunction, which are all diseases 
which have been associated with low 25(OH)D levels.18 As 
such, these are areas that require further investigation.
Our data confirm previous observations regarding a high 
prevalence of what is traditionally considered a suboptimal 
25(OH)D level of ,30 ng/mL. We were not able to explain 
the reasons for low 25(OH)D levels, as we did not collect 
information on common factors affecting vitamin D status, 
such as dietary supplement use, sunlight exposure, and skin 
pigmentation. We also note that while we found a high preva-
lence of 25(OH)D levels ,30 ng/mL in our sample of patients 
with COPD, general population samples have also demon-
strated a high prevalence of low 25(OH)D   levels. Among 
13,369 US participants in the National Health and Nutrition 
Examination Survey (NHANES) between 2001–2004, 77% 
had levels ,30 ng/mL.19
responses may be different in asthma and COPD, but there 
are currently no published reports regarding this topic among 
patients with COPD.
This is the first study to analyze 25(OH)D levels in 
relation to ICS responses in COPD. This study has several 
  limitations. The study sample was essentially limited to 
elderly Caucasian males and was a single-center study. Our 
study was also relatively small in size, but all of our point 
estimates for differences clustered around the null hypothesis 
of no difference. As such, a larger sample size would not 
likely alter the conclusions. In addition, FEV1 responses were 
only assessed over a relatively brief 4-week ICS intervention; 
longer-term outcome data were not collected. The rationale 
for this brief intervention was that the majority of ICS effects 
on FEV1 have occurred within 2–4 weeks in previous large 
COPD clinical trials.15–17
The need for an ICS wash-out period may have also 
affected our results. Patients with previous good   clinical 
responses to ICS therapy may have been either less likely 
to enroll in this study or more likely to withdraw   during 
the study, as was suggested by the higher percent of pre-
vious ICS users in the group that did not complete the 
study. Thus, our sample may have been biased towards 
ICS nonresponders. A 4-week period for ICS wash-out 
could also limit ICS responses following re-introduction 
of ICS therapy. A study of ICS-naive patients would have International Journal of COPD
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In summary, there was a high prevalence of low blood 
25(OH)D levels in a sample of patients with severe COPD, 
and these 25(OH)D levels were not associated with   short-term 
FEV1 responses to ICS therapy.
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